Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR R1032Q |
| Therapy | Pazopanib |
| Indication/Tumor Type | basal cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR R1032Q | basal cell carcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, Votrient (pazopanib) treatment in a patient with metastatic basal cell carcinoma harboring KDR R1032Q who had progressed on treatment with Erivedge (vismodegib), resulted in a complete response, but treatment was discontinued after 6 months due to toxic effects, and disease relapse followed 3 months later (PMID: 28384659). | 28384659 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28384659) | Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. | Full reference... |